TY - JOUR
T1 - Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
AU - Hanamura, Toru
AU - Kitano, Shigehisa
AU - Kagamu, Hiroshi
AU - Yamashita, Makiko
AU - Terao, Mayako
AU - Tsuda, Banri
AU - Okamura, Takuho
AU - Kumaki, Nobue
AU - Hozumi, Katsuto
AU - Harada, Naoki
AU - Iwamoto, Takayuki
AU - Honda, Chikako
AU - Kurozumi, Sasagu
AU - Niikura, Naoki
N1 - Funding Information:
We would like to thank Editage ( www.editage.com ) for English language editing. This study was supported by the Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (Project No. 18K16266; to NN), and the 2020 Tokai University School of Medicine Research Aid (to TH). This work was also supported by Chugai Pharmaceutical Co., Ltd.
Funding Information:
Hiroshi Kagamu has an advisory role in ImmuniT Research Inc. Naoki Harada received a salary from Chugai Pharmaceutical. Shigehisa Kitano received honoraria from Ono Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and MSD Co., Ltd. Hiroshi Kagamu received honoraria from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co., Ltd. Naoki Niikura received honoraria from AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., and Nippon Kayaku Co., Ltd. Shigehisa Kitano received research funding from Astellas Pharma Inc., Gilead Sciences Inc., Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmgH, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Takara Bio Inc., PACT Pharma, Inc., Chugai Pharmaceutical Co., Ltd., and MSD Co., Ltd. Naoki Niikura received research funding from Chugai Pharmaceutical Co., Ltd. The remaining authors declare no competing interests.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Tumor-infiltrating lymphocytes (TILs) and programmed cell death 1 ligand 1 (PD-L1) are established prognostic and predictive biomarkers for certain breast cancer subsets. However, their association with the immune response complexity is not fully understood. Therefore, we analyzed the association between the immune cell fractions in breast cancer tissues and histologically assessed TIL (hTIL) and PD-L1 (hPD-L1). Forty-five tumor and eighteen blood samples were collected from patients with breast cancer. Total leukocyte counts, frequency of 11 immune cell populations, and PD-L1 expression in each cell fraction were evaluated by flow cytometry. TILs and PD-L1 were assessed by hematoxylin and eosin staining and immunohistochemistry, respectively. A higher hTIL score showed association with increased leukocyte infiltration, higher CD4+ and CD8+ T cell proportions, and lower natural killer and natural killer T cell proportions. PD-L1 was highly expressed in nonclassical monocytes, monocyte/macrophages, myeloid-derived suppressor cells, myeloid dendritic cells, dendritic cells, and other lineages in tumors. hPD-L1 positivity reflected PD-L1 expression accurately in these fractions, as well as increased leukocyte infiltration in tumors. These results indicate that hTILs reflect differences in the immune responses in the tumor microenvironment, and certain immune cell fractions are favorably expressed in the PD-L1 pathway in breast cancer microenvironments.
AB - Tumor-infiltrating lymphocytes (TILs) and programmed cell death 1 ligand 1 (PD-L1) are established prognostic and predictive biomarkers for certain breast cancer subsets. However, their association with the immune response complexity is not fully understood. Therefore, we analyzed the association between the immune cell fractions in breast cancer tissues and histologically assessed TIL (hTIL) and PD-L1 (hPD-L1). Forty-five tumor and eighteen blood samples were collected from patients with breast cancer. Total leukocyte counts, frequency of 11 immune cell populations, and PD-L1 expression in each cell fraction were evaluated by flow cytometry. TILs and PD-L1 were assessed by hematoxylin and eosin staining and immunohistochemistry, respectively. A higher hTIL score showed association with increased leukocyte infiltration, higher CD4+ and CD8+ T cell proportions, and lower natural killer and natural killer T cell proportions. PD-L1 was highly expressed in nonclassical monocytes, monocyte/macrophages, myeloid-derived suppressor cells, myeloid dendritic cells, dendritic cells, and other lineages in tumors. hPD-L1 positivity reflected PD-L1 expression accurately in these fractions, as well as increased leukocyte infiltration in tumors. These results indicate that hTILs reflect differences in the immune responses in the tumor microenvironment, and certain immune cell fractions are favorably expressed in the PD-L1 pathway in breast cancer microenvironments.
UR - http://www.scopus.com/inward/record.url?scp=85130037613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130037613&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-11578-x
DO - 10.1038/s41598-022-11578-x
M3 - Article
C2 - 35577913
AN - SCOPUS:85130037613
SN - 2045-2322
VL - 12
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 8098
ER -